Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
The First Affiliated Hospital of Soochow University
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Indicative
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hemophagocytic Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rituximab (this asset) | The First Affiliated Hospital of Soochow University | Approved | BB · 64 |
| Etoposide | Beijing Tongren Hospital | P4 | BBB |
| Pegaspargase | Beijing Tongren Hospital | P4 | BB |
| Adriamycin | The First Affiliated Hospital of Soochow University | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | Zhengzhou University | P4 | BB |
| Zanubrutinib | The First Affiliated Hospital of Soochow University | P4 | BB |
| Dexasone | Zhengzhou University | P4 | BB |
| Thiotepa | University of Florida | P2 | BB |
| Ruxolitinib | Zhengzhou University | P4 | B |
+23 more in the Hemophagocytic Syndrome cohort
Other indications for Rituximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lymphoblastic Lymphoma | — | P4 | BBB · 75 |
| Grade III Lymphomatoid Granulomatosis | — | P2 | BBB · 74 |
| Testicular Lymphoma | — | P2 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rituximab in Hemophagocytic Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g-1-human-mouse-monoclonal-idec-c2b8-gamma1-chain-anti-human-antigen-cd-20-disulfide-with-human-mouse-monoclonal-idec-c2b8-kappa-chain-dimer-hemophagocytic-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →